Chronic hyperhomocysteinemia provokes a memory deficit in rats in the Morris water maze task

Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo, CEP 90035-003, Porto Alegre, RS, Brazil.
Behavioural Brain Research (Impact Factor: 3.39). 09/2004; 153(2):377-81. DOI: 10.1016/j.bbr.2003.12.013
Source: PubMed

ABSTRACT Homocystinuria is an inherited metabolic disease biochemically characterized by tissue accumulation of homocysteine. Affected patients present mental retardation and other neurological symptoms whose mechanisms are still obscure. In the present study, we investigated the effect of chronic hyperhomocysteinemia on rat performance in the Morris water maze task. Chronic treatment was administered from the 6th to the 28th day of life by s.c. injection of homocysteine, twice a day at 8-h intervals; control rats received the same volume of saline solution. Animals were left to recover until the 60th day of life. Morris water maze tasks were then performed, in order to verify any effect of early homocysteine administration on reference and working memory of rats. Results showed that chronic treatment with homocysteine impaired memory of the platform location and that homocysteine treated animals presented fewer crossings to the place where the platform was located in training trials when compared to saline-treated animals (controls). In the working memory task, homocysteine treated animals also needed more time to find the platform. Our findings suggest that chronic experimental hyperhomocysteinemia causes cognitive dysfunction and that might be related to the neurological complications characteristic of homocystinuric patients.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in the understanding of the pathophysiological mechanisms underlying Alzheimer's disease and other cognitive deficits have pointed to novel strategies for drug development. Animal models have contributed noticeably to these advances and are an indispensible part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia, and discussion about their role in drug discovery and development have been carried out. Since dementia has multiple pathophysiological mechanisms, we have tried to provide a detailed description of various types of animal models which would depict different pathophysiological stages and causes of dementia. This review aims to better understand the prognosis, biochemical, and behavioral alterations that occur during dementia and hence facilitate drug discovery and development.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Studies demonstrated that chronic high-dose homocysteine administration induced learning and memory impairment in animals. Atractylenolide III, a neuroprotective constituent of Atractylodis macrocephalae Koidz, was isolated in our previous study. In this study, we investigated potential benefits of atractylenolide III in preventing the expected learning and memory impairment following chronic high-dose homocysteine administration in rats. The results showed that administration of atractylenolide III significantly ameliorated learning and memory impairment induced by chronic high-dose homocysteine administration in rats, decreased homocysteine-induced reactive oxygen species (ROS) formation and restored homocysteine-induced decrease of phosphorylated protein kinase C expression level. Moreover, atractylenolide III protected primary cultured neurons from apoptotic death induced by homocysteine treatment. This study provide first evidence for the neuroprotective effect of atractylenolide III in preventing learning and impairment induced by chronic administration of homocysteine. Atractylenolide III may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury. Copyright © 2015. Published by Elsevier Ltd.
    Neuroscience 02/2015; 290. DOI:10.1016/j.neuroscience.2015.01.060 · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although homocysteine (Hcy) has been widely implicated in the etiology of various physical health impairments, especially cardiovascular diseases, overwhelming evidence indicates that Hcy is also involved in the pathophysiology of schizophrenia and affective disorders. There are several mechanisms linking Hcy to biological underpinnings of psychiatric disorders. It has been found that Hcy interacts with NMDA receptors, initiates oxidative stress, induces apoptosis, triggers mitochondrial dysfunction and leads to vascular damage. Elevated Hcy levels might also contribute to cognitive impairment that is widely observed among patients with affective disorders and schizophrenia. Supplementation of vitamins B and folic acid has been proved to be effective in lowering Hcy levels. There are also studies showing that this supplementation strategy might be beneficial for schizophrenia patients with respect to alleviating negative symptoms. However, there are no studies addressing the influence of add-on therapies with folate and vitamins B on cognitive performance of patients with schizophrenia and affective disorders. In this article, we provide an overview of Hcy metabolism in psychiatric disorders focusing on cognitive correlates and indicating future directions and perspectives.
    Frontiers in Behavioral Neuroscience 09/2014; DOI:10.3389/fnbeh.2014.00343 · 4.16 Impact Factor